Curis (NASDAQ:CRIS) Issues Earnings Results

Curis (NASDAQ:CRIS) released its earnings results on Tuesday. The biotechnology company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.92), FiscalAI reports.

Curis Stock Down 0.1%

Shares of CRIS traded down $0.00 during mid-day trading on Tuesday, hitting $0.55. 287,114 shares of the company traded hands, compared to its average volume of 574,140. Curis has a 1-year low of $0.49 and a 1-year high of $3.13. The company has a market capitalization of $22.00 million, a PE ratio of -0.46 and a beta of 3.08. The business has a 50 day moving average of $0.71 and a 200 day moving average of $0.99.

Institutional Investors Weigh In On Curis

Several hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC lifted its position in shares of Curis by 8.7% during the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 78,265 shares in the last quarter. Maverick Capital Ltd. lifted its holdings in Curis by 7.8% in the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after purchasing an additional 49,554 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Curis by 37.3% in the 4th quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after purchasing an additional 65,404 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Curis by 2,883,237.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 230,659 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in Curis by 17.9% in the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 8,973 shares in the last quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Curis in a research report on Friday, March 20th. Wall Street Zen upgraded shares of Curis to a “hold” rating in a research report on Saturday, March 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Curis presently has a consensus rating of “Hold” and a consensus price target of $17.00.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.